The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC reduced its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,738 shares of the medical device company’s stock after selling 838 shares during the period. TD Private Client Wealth LLC’s holdings in Cooper Companies were worth $2,458,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Byrne Asset Management LLC acquired a new position in shares of Cooper Companies during the 4th quarter worth approximately $33,000. OFI Invest Asset Management acquired a new position in shares of Cooper Companies during the 4th quarter worth approximately $34,000. Brown Brothers Harriman & Co. boosted its holdings in shares of Cooper Companies by 191.0% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after purchasing an additional 275 shares during the last quarter. West Financial Advisors LLC acquired a new position in shares of Cooper Companies during the 4th quarter worth approximately $49,000. Finally, Atala Financial Inc purchased a new stake in shares of Cooper Companies during the 4th quarter valued at approximately $51,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Stock Up 1.6 %

Shares of NASDAQ COO opened at $81.71 on Friday. The firm has a market cap of $16.34 billion, a price-to-earnings ratio of 41.90, a PEG ratio of 2.25 and a beta of 1.02. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The Cooper Companies, Inc. has a 52-week low of $77.05 and a 52-week high of $112.38. The business’s 50 day moving average is $90.05 and its two-hundred day moving average is $98.14.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The business had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Research analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Analyst Ratings Changes

COO has been the topic of several analyst reports. Citigroup reduced their price target on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Morgan Stanley reduced their price target on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Robert W. Baird reduced their price target on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research report on Friday, March 7th. Finally, StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.